SecBot SecBot
Biotech Drug Report Generated Aug 3, 2026

Venclexta

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved (marketed); supplemental/expansion trials Phase 3
Time to market
Already on the market, accelerated US approval 2016 (17p-deleted CLL), broader CLL/SLL approval 2019, AML approvals since 2018-2020, and newest first-line CLL combo approval February 2026.
Why 4/10
No hard, dated binary for Venclexta in the next ~12 months: the most recent catalyst, FDA approval of the Venclexta + acalabrutinib first-line CLL combo, already passed (Feb 19-20, 2026), the VERONA MDS expansion trial failed, and the drug is one (solid but minority) franchise inside mega-cap AbbVie, so impactScore sits mid-range at 4.
Actionable Insight NEUTRAL

The defining approvals are already in: Venclexta is a marketed CLL/AML franchise with a fresh US label expansion (first-line CLL combo, Feb 2026), so there is no pending PDUFA-style binary to trade, the next meaningful moves will come from quarterly hematology revenue commentary and competitive data from next-generation BCL-2 inhibitors (e.g., BeiGene's sonrotoclax). ABBV's stock is driven far more by its immunology portfolio (Skyrizi/Rinvoq) than by Venclexta, so position sizing should treat this drug as steady cash flow, not a swing factor.

Price Chart

Loading chart...

Executive Summary

Venclexta (venetoclax, also sold as Venclyxto outside the US) is an approved oral BCL-2 inhibitor for chronic lymphocytic leukemia/small lymphocytic lymphoma and acute myeloid leukemia, developed by AbbVie with Roche/Genentech, confirmed via FDA pages, AbbVie press releases, and SecBot's FDA-catalyst log. In February 2026 the FDA approved the all-oral, fixed-duration Venclexta + acalabrutinib combo for previously untreated CLL, and nine-year CLL14 data were showcased at EHA 2026, but the Phase 3 VERONA trial failed to improve survival in myelodysplastic syndrome, a setback for label expansion. ABBV (NYSE, confirmed live issuer) trades near $251 with a buy-rated analyst consensus (mean target ~$270), but Venclexta is one of several growth franchises inside the mega-cap, so it has no near-term binary catalyst.

How It Works

A once-daily pill that blocks a protein called BCL-2, which acts as a "survival switch" inside cancer cells. Blocking it makes leukemia/lymphoma cells self-destruct while leaving most healthy cells alone; it is used alone or combined with other cancer drugs (e.g., acalabrutinib, obinutuzumab, azacitidine).

Trial Status

FDA approved the Venclexta + acalabrutinib sNDA for previously untreated CLL in Feb 2026 (Phase 3 AMPLIFY data); final 9-year results from the Phase 3 CLL14 first-line CLL trial were presented at EHA June 2026; Phase 3 VERONA trial (venetoclax + azacitidine in higher-risk MDS) showed no overall survival benefit, presented 2025; AbbVie presented Phase 3 CANOVA results (relapsed/refractory multiple myeloma, t(11;14)) in 2023; a post-transplant AML maintenance Phase 3 study was terminated.

The Two-Sided Case

▲ Bull Case5
Approved, established franchise: FDA-approved for CLL/SLL (2019) and AML, supplied by AbbVie (Drugs.com history; FDA pages).
Fresh US label expansion: FDA approved the Venclexta + acalabrutinib combination for previously untreated CLL in Feb 2026, first all-oral, fixed-duration regimen in that setting, supported by Phase 3 AMPLIFY (AbbVie/Genentech press releases).
Durable efficacy data: final 9-year results from the Phase 3 CLL14 trial presented at EHA 2026 support long-term treatment outcomes in first-line CLL (AbbVie release).
SecBot's FDA-catalyst log records a positive reaction to the combo approval: +6.89% 1-day and +5.30% 5-day around the logged event (price ~$197.69 pre).
Sponsor strength: AbbVie is a large-cap with buy-rated consensus (22 buy, 9 strong buy, 0 sell; mean price target $270.39 vs $250.94 price) and 12-month return of +36.67% per quant data.
▼ Bear Case5
Expansion setback: Phase 3 VERONA showed venetoclax + azacitidine did NOT improve overall survival in higher-risk MDS vs placebo, no MDS label expansion (Dana-Farber release; CURE Today).
Competitive threat: next-generation BCL-2 inhibitors (notably BeiGene's sonrotoclax) are advancing in CLL and could undercut Venclexta's pricing/positioning over time.
No pending regulatory binary: the defining approvals have passed, so the stock gets no Venclexta-specific PDUFA/readout catalyst in the next ~12 months; the Phase 3 CANOVA multiple-myeloma program has not produced a filing, and a post-transplant AML Phase 3 was terminated.
Small share of a huge company: Venclexta is a modest part of ~$68B+ revenue AbbVie (2026 consensus ~$67.6B, +10.5% growth), so even good news moves ABBV little; 2026-Q2 13F data show several tracked funds trimming ABBV positions.
Drug-specific risk: some Phase 2/3 venetoclax studies in other blood cancers (mantle cell lymphoma, MDS settings) have been terminated or completed without positive results per local ClinicalTrials.gov records.

Upcoming Catalysts

  • Quarterly earnings commentary on hematology-oncology revenue (Q2 2026 8-K filed July 31, 2026; FY2026 revenue consensus ~$67.6B).
  • Potential ex-US (e.g., EMA) regulatory actions on the Venclexta + acalabrutinib first-line CLL combo, no confirmed date from sources reviewed.
  • Competitive readouts from next-gen BCL-2 inhibitors (sonrotoclax) that could pressure the CLL market.
  • Any follow-on filings from VERONA (MDS, unlikely after the survival miss) or CANOVA (multiple myeloma), both currently lack a dated submission.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 14

Hover a chip for the title
1 drugs.com2 news.abbvie.com3 gene.com4 fda.gov5 fda.gov6 accessdata.fda.gov7 news.abbvie.com8 news.abbvie.com9 dana-farber.org10 curetoday.com11 news.abbvie.com12 nejm.org13 prnewswire.com14 oncodaily.com